Norinyl (Ortho Novum)

07/01/1979 - " Overall in both study populations, Ovral affected significantly more users (P .05) both with regard to chloasma and all skin conditions than did Norinyl. "
07/01/1979 - " Women using Ovral in Costa Rica reported acne and chloasma in significantly greater (P .001) numbers than did women using Norinyl. "

05/01/1992 - " Because the triphasic OC preparation possible precipitated her panic disorder with agoraphobia, she was changed to Ortho-Novum 1/35 OC which has markedly improved her anxiety for 2 years now."

05/01/1992 - " Because the triphasic OC preparation possible precipitated her panic disorder with agoraphobia, she was changed to Ortho-Novum 1/35 OC which has markedly improved her anxiety for 2 years now."

07/01/1979 - " Women using Ovral in Costa Rica reported acne and chloasma in significantly greater (P .001) numbers than did women using Norinyl. "

11/01/1991 - "Significantly more women in the Norinyl 1+35 group (p less than .001) reported intermenstrual bleeding (primarily staining and spotting), as well as an increase in the occurrence of intermenstrual bleeding compared to women in the Norinyl 1+50 group. "
07/01/1979 - "A higher percentage of women using Norinyl reported intermenstrual bleeding and spotting in both countries. "
10/12/1984 - " In multicenter randomized trials involving Ortho-Novum 7/7/7, 2 pregnancies occurred in 294 women and the incidence of breakthrough bleeding was either comparable to or less than that found in women taking Ortho-Novum 1/35 and 10/11, respectively. "
11/01/1988 - "Intermenstrual bleeding was reported by significantly more women in the Brevicon group than in the Norinyl group (p less than 0.05), and significantly more Brevicon users reported an increase in intermenstrual bleeding. "
05/01/1983 - " Breakthrough bleeding was more common among Brevicon users than Norinyl users, and most other side effects were more frequent among Norinyl users, although these latter differences were quite small and there were several exceptions. "